TerminatedPhase 3NCT03948178
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Orion Corporation, Orion Pharma
- Principal Investigator
- Geneviève Nadeau, CSDOrion Corporation, Orion Pharma
- Intervention
- Levosimendan(drug)
- Enrollment
- 227 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2019 – 2020
Study locations (30)
- Neuromuscular research Centre and Neuromuscular Clinic of Arizona, Phoenix, Arizona, United States
- University of California San Diego, La Jolla, California, United States
- University of California Irvine Medical Center, Orange, California, United States
- Hospital for Special Care, New Britain, Connecticut, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- The George Washington Medical Faculty Associates, Washington D.C., District of Columbia, United States
- Holy Cross Hospital Neuroscience Institute, Fort Lauderdale, Florida, United States
- University of Florida McKnight Brain Institute, Gainesville, Florida, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- University of South Florida/USF Health, Tampa, Florida, United States
- Augusta University, Medical Centre, Augusta, Georgia, United States
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03948178 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07259980A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)Biogen
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)